Cargando…

Direct‐acting antivirals ability to clear intestinal HCV‐RNA in liver transplant patients

The hepatitis C virus mainly infects the liver but is also able to infect and replicate in other body compartments by creating an extra‐hepatic reservoir that may influence the persistence of the infection after transplantation. It is unknown whether antiviral drugs affect the viral extra‐hepatic si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pietrosi, Giada, Russelli, Giovanna, Barbera, Floriana, Curcio, Gabriele, Tuzzolino, Fabio, Gallo, Alessia, Volpes, Riccardo, Vizzini, Giovanni, Conaldi, Pier Giulio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685120/ https://www.ncbi.nlm.nih.gov/pubmed/32495971 http://dx.doi.org/10.1111/tid.13345

Ejemplares similares

HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation
por: Russelli, Giovanna, et al.
Publicado: (2017)

Clinical and Molecular-Based Approach in the Evaluation of Hepatocellular Carcinoma Recurrence after Radical Liver Resection
por: Gruttadauria, Salvatore, et al.
Publicado: (2021)

Successful Use of Heterologous CMV-Reactive T Lymphocyte to Treat Severe Refractory Cytomegalovirus (CMV) Infection in a Liver Transplanted Patient: Correlation of the Host Antiviral Immune Reconstitution with CMV Viral Load and CMV miRNome
por: Miele, Monica, et al.
Publicado: (2021)

Hepatocellular carcinoma, hepatitis C virus infection and miRNA involvement: Perspectives for new therapeutic approaches
por: Badami, Ester, et al.
Publicado: (2022)

Human Amnion-Derived Mesenchymal Stromal Cells in Cirrhotic Patients with Refractory Ascites: A Possible Anti-Inflammatory Therapy for Preventing Spontaneous Bacterial Peritonitis
por: Pampalone, Mariangela, et al.
Publicado: (2021)

Mesenchymal stromal cell secretome in liver failure: Perspectives on COVID-19 infection treatment
por: Chinnici, Cinzia Maria, et al.
Publicado: (2021)

Gathering Novel Circulating Exosomal microRNA in Osteosarcoma Cell Lines and Possible Implications for the Disease
por: Cuscino, Nicola, et al.
Publicado: (2019)

Role of Allelic Imbalance in Predicting Hepatocellular Carcinoma (HCC) Recurrence Risk After Liver Transplant
por: Pagano, Duilio, et al.
Publicado: (2019)

Zika Virus: A New Therapeutic Candidate for Glioblastoma Treatment
por: Francipane, Maria Giovanna, et al.
Publicado: (2021)

Human Amnion-Derived Mesenchymal Stromal Cells: A New Potential Treatment for Carbapenem-Resistant Enterobacterales in Decompensated Cirrhosis
por: Pampalone, Mariangela, et al.
Publicado: (2022)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Cognitive outcomes in patients treated with neuromuscular electrical stimulation after coronary artery bypass grafting
por: Lo Re, Vincenzina, et al.
Publicado: (2023)

Circulating miRNAs as Promising Biomarkers to Evaluate ECMO Treatment Responses in ARDS Patients
por: Martucci, Gennaro, et al.
Publicado: (2021)

Long-Term Effectiveness of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine on B Cell Compartment: Efficient Recall of SARS-CoV-2-Specific Memory B Cells
por: Busà, Rosalia, et al.
Publicado: (2022)

HCV Interplay With Mir34a: Implications in Hepatocellular Carcinoma
por: Badami, Ester, et al.
Publicado: (2022)

Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components
por: Busà, Rosalia, et al.
Publicado: (2022)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Identification of a Circulating miRNA Signature to Stratify Acute Respiratory Distress Syndrome Patients
por: Martucci, Gennaro, et al.
Publicado: (2020)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Non-Coding RNAs: Strategy for Viruses’ Offensive
por: Gallo, Alessia, et al.
Publicado: (2020)

Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients
por: Miele, Monica, et al.
Publicado: (2021)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV–HCV Coinfected Patients
por: Tripathi, Gaurav, et al.
Publicado: (2022)

Galectin-9 and Interferon-Gamma Are Released by Natural Killer Cells upon Activation with Interferon-Alpha and Orchestrate the Suppression of Hepatitis C Virus Infection
por: Carreca, Anna Paola, et al.
Publicado: (2022)

Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank
por: Kliemann, Dimas Alexandre, et al.
Publicado: (2016)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
por: Fabrizi, Fabrizio, et al.
Publicado: (2019)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020)

Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study
por: Messina, Vincenzo, et al.
Publicado: (2020)

356. HIV-HCV Coinfection: An Investigation of CD4 T-Cell Reconstitution after HCV Direct-Acting Antiviral Treatment
por: Michienzi, Sarah M, et al.
Publicado: (2019)

T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy
por: Auma, Ann W N, et al.
Publicado: (2021)

HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection
por: Basso, Monica, et al.
Publicado: (2021)

Viral miRNAs as Active Players and Participants in Tumorigenesis
por: Gallo, Alessia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b8k8oh0dt8ur8arclhrj50v3er